lncRNA ROR Promotes Gastric Cancer Drug Resistance
Objective: Gastric cancer is one of the most common malignant tumors worldwide, and for resectable tumors, the most effective treatment is surgery with chemotherapy in neoadjuvant or adjuvant setting. However, the majority of patients fail to achieve the ideal initial response and/or develop resista...
Main Authors: | Shuai Wang PhD, Wujun Chen MD, Hualong Yu PhD, Zhengming Song MD, Qian Li PhD, Xin Shen PhD, Yudong Wu PhD, Lei Zhu PhD, Qingxia Ma PhD, Dongming Xing PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-01-01
|
Series: | Cancer Control |
Online Access: | https://doi.org/10.1177/1073274820904694 |
Similar Items
-
A Novel LncRNA SNHG3 Promotes Osteoblast Differentiation Through BMP2 Upregulation in Aortic Valve Calcification
by: Long Chen, MD, et al.
Published: (2022-09-01) -
LncRNA NONHSAT227443.1 Confers Esophageal Squamous Cell Carcinoma Chemotherapy Resistance by Activating PI3K/AKT Signaling via Targeting MRTFB
by: Yuchen Wang PhD, et al.
Published: (2024-08-01) -
COLEC12 Promotes Tumor Progression and Is Correlated With Poor Prognosis in Gastric Cancer
by: Xiangfei Sun PhD, et al.
Published: (2023-12-01) -
Gel immersion EMR for hemorrhagic gastric hyperplastic polyp
by: Naoki Akizue, MD, PhD, et al.
Published: (2024-07-01) -
Oncological Impact of Gross Proximal Margin Length in Distal Gastrectomy for Gastric Cancer: Is the Japanese Recommendation Valid?
by: Masaru Hayami, MD, PhD, et al.
Published: (2021-03-01)